Biopolym. Cell. 2011; 27(3):231-234.
http://dx.doi.org/10.7124/bc.0000BE
Short Communications
IFN-λ-3 (IL28B) genotyping by restriction fragment length polymorphism method: detection polymorphism of rs12979860
1Pampukha V. M., 1Kravchenko S. A., 2Moroz L. V., 1Livshits L. A.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. National Pirogov Memorial Medical University NAMS of Ukraine
    56, Pirogova Str., Vinnytsya, Ukraine, 21018

Abstract

Aim. The goal of our study was to develop an accurate detection of the SNP rs12979860 by RFLP-based method and to evaluate the polymorphic genotype distribution for this SNP among individuals with unknown HCV status from Ukraine. Methods.The SNP rs12979860 was tested by PCR RFLP-based method in 99 individuals from Ukraine. Results. The method of accurate detection of the SNP rs12979860 was developed. The genotypes distributions were: CC – 56 %, CT – 34 %, TT – 10 %. Conclusions. Due to the high incidence of CC genotype, found in our study, the SNP rs12979860 analysis may be useful for Ukrainian patients to predict responses to the treatment considering the HCV genotype and viral load.
Keywords: IFN-λ-3 (IL28B) gene, SNP rs12979860, PCR-RFLP method, hepatitis C
Full text: (PDF, in English)

References

[1] World Health Organization: Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium J. Viral. Hepat 1999 6, N 1 P. 35–47.
[2] Micallef J. M., Kaldor J. M., Dore G. J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies J. Viral. Hepat 2006 13, N 1 P. 34–41.
[3] Gural A. L., Marievskiy V. F., Sergeyeva T. A., Shaginyan V. R., Ruban O. M. Characteristics and trends of hepatitis' C epidemic process in Ukraine Preventive Medicine 2011 N 1 P. 9–17.
[4] Thomas D. L., Seeff L. B. Natural history of hepatitis C Clin. Liver Dis 2005 9, N 3 P. 383–398.
[5] Di Bisceglie A. M., Hoofnagle J. H. Optimal therapy of hepatitis C Hepatology 2002 36 (5 Suppl 1) P. S121–127.
[6] Zeuzem S., Berg T., Moeller B., Hinrichsen H., Mauss S., Wedemeyer H., Sarrazin C., Hueppe D., Zehnter E., Manns M. P. Expert opinion on the treatment of patients with chronic hepatitis C J. Viral. Hepat 2009 16, N 2 P. 75–90.
[7] Ge D., Fellay J., Thompson A. J., Simon J. S., Shianna K. V., Urban T. J., Heinzen E. L., Qiu P., Bertelsen A. H., Muir A. J., Sulkowski M., McHutchison J. G., Goldstein D. B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 2009 461, N 7262 P. 399–401.
[8] Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M. L., Bassendine M., Spengler U., Dore G. J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Muller T., Bahlo M., Stewart G. J., Booth D. R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat. Genet 2009 41, N 10 P. 1100–1104.
[9] Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat. Genet 2009 41, N 10 P. 1105–1109.
[10] Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J. F., Furrer H., Gunthard H. F., Heim M., Hirschel B., Malinverni R., Moradpour D., Mullhaupt B., Witteck A., Beckmann J. S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P. Y.; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 2010 138, N 4 P. 1338– 1345.
[11] Thomas D. L., Thio C. L., Martin M. P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S. I., Alexander G., Goedert J. J., Kirk G. D., Donfield S. M., Rosen H. R., Tobler L. H., Busch M. P., McHutchison J. G., Goldstein D. B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 2009 461, N 7265 P. 798–801.
[12] Sambrook J., Frtsch E. F., Maniatis T. Molecular cloning: a laboratory manual New York: Cold Spring Harbor Lab. press, 1989 253 p.
[13] Weir B. S. Genetic data analysis. Methods for discrete population genetic data Sunderland: Sinauer Associates, Inc. Publ., 1990 377 p.
[14] Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T. E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D. IL-28, IL-29 and their class II cytokine receptor IL-28R Nat. Immunol 2003 4, N 1 P. 63–68.
[15] Fox B. A., Sheppard P. O., O'Hara P. J. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family PLoS One 2009 4, N 3 e4933.